Endre Grvik1, Kathinka Kurz Dhli2, Atle Bjrnerud3, Kjell-Inge Gjesdal4
1University of Oslo, Oslo, Norway; 2Stavanger University Hospital, Stavanger, Norway; 3Rikshospitalet University Hospital, Oslo, Norway; 4Sunnmre MR-klinikk, Aalesund, Norway
This work presents the transverse relaxation rate, R2*, as a quantitative biomarker for distinguishing between malignant and benign breast lesions. R2* was estimated on a pixel-by-pixel basis by assuming a mono-exponential dependence of a double-echo intensity scheme, yielding from a high temporal resolution sequence. The study suggested that the peak change in the transverse relaxation rate is a sensitive biomarker for tumor malignancy in DSC MR-mammography.